List of Excipients in Branded Drug YUVAFEM

Generic Drugs Containing YUVAFEM

Company	Ingredient	NDC	Excipient
AvKARE	estradiol	42291-962	HYPROMELLOSES
AvKARE	estradiol	42291-962	LACTOSE MONOHYDRATE
AvKARE	estradiol	42291-962	MAGNESIUM STEARATE
AvKARE	estradiol	42291-962	POLYETHYLENE GLYCOL
AvKARE	estradiol	42291-962	STARCH, CORN
Amneal Pharmaceuticals LLC	estradiol	65162-226	HYPROMELLOSES
Amneal Pharmaceuticals LLC	estradiol	65162-226	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in YUVAFEM?

# Of NDCs	Excipient
2	HYPROMELLOSES
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE
2	POLYETHYLENE GLYCOL
2	STARCH, CORN

Yuvafem Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Yuvafem is a 10-mcg estradiol vaginal insert for moderate-to-severe vulvar and vaginal atrophy caused by menopause. Its commercial value is tied to low-dose delivery, limited systemic exposure, patient convenience, and a formulation that avoids creams and applicator-filled gels. The core excipient strategy should preserve the established vaginal-tablet profile while creating differentiation through stability, manufacturability, packaging, and delivery-system improvements.

What is Yuvafem and how is it regulated?

Yuvafem contains 10 mcg of estradiol in a vaginal insert administered once daily for two weeks, followed by twice-weekly maintenance dosing under the U.S. prescribing information. It is an FDA-approved prescription drug, not a biologic, so biosimilar regulation does not apply. Generic competition proceeds through the abbreviated new drug application, or ANDA, pathway rather than through a biosimilar application.[1]

Attribute	Yuvafem
Active ingredient	Estradiol
Strength	10 mcg per vaginal insert
Dosage form	Vaginal insert/tablet
Route	Intravaginal
Reference product	Vagifem, historically marketed by Novo Nordisk
FDA pathway	NDA reference product; generic products use ANDA
Primary indication	Menopausal vulvar and vaginal atrophy
Typical maintenance schedule	One insert twice weekly after initial treatment
Biosimilar exposure	None
Key commercial comparators	Vagifem, generic estradiol vaginal inserts, estradiol creams, vaginal rings, prasterone vaginal inserts, ospemifene tablets

Yuvafem is listed in FDA product information as estradiol vaginal inserts. The relevant regulatory benchmark is pharmaceutical equivalence to the reference listed drug, including strength, dosage form, route, and active ingredient.[1,2]

What excipients are used in Yuvafem?

The Yuvafem insert uses a compact solid-dosage formulation. Public labeling identifies lactose monohydrate, hypromellose, magnesium stearate, and polyethylene glycol among the inactive ingredients.[3]

Excipient	Likely formulation function	Strategic relevance
Lactose monohydrate	Diluent and tablet-mass former	Supports low-dose content uniformity and compact tablet manufacture
Hypromellose	Binder and release-controlling polymer	Contributes to tablet integrity and hydration behavior
Magnesium stearate	Lubricant	Supports compression and ejection, but excessive use can slow wetting
Polyethylene glycol	Binder, plasticizer, film or matrix aid	Supports tablet processing and surface characteristics

The main formulation challenge is the very low estradiol load. At 10 mcg per unit, the active ingredient represents a small fraction of the tablet mass. Excipient selection therefore directly affects blend uniformity, dose accuracy, content uniformity, dissolution, and stability.

The formulation also has a practical advantage over semi-solid vaginal products. It avoids the preservative systems, oil-water emulsion structure, and larger patient-administered volume associated with many vaginal creams.

How should an excipient strategy be designed for Yuvafem?

The strongest strategy is a two-track model: preserve the reference formulation for regulatory efficiency while developing a differentiated platform for future products.

Track one: reference-aligned formulation

A generic or authorized-generic developer should minimize unnecessary excipient changes. A composition aligned with the reference product can reduce risks involving:

• Comparative dissolution
• Content uniformity
• Tablet disintegration
• Vaginal residence time
• Stability
• Local irritation
• Extractables and leachables
• ANDA product-quality review

For a low-dose vaginal insert, direct substitution of excipients can create disproportionate technical risk. A different lactose grade, hypromellose viscosity grade, magnesium stearate source, or polyethylene glycol molecular weight can alter compression, wetting, dissolution, and dose distribution.

The preferred development sequence is:

1. Match the qualitative excipient profile.
2. Optimize excipient grades and processing parameters.
3. Establish blend uniformity and segregation controls.
4. Confirm dissolution and disintegration against the reference product.
5. Conduct local tolerability and compatibility assessments.
6. Change excipients only where there is a clear commercial or regulatory benefit.

Track two: differentiated vaginal-insert platform

A company seeking lifecycle value should investigate changes that improve patient use without materially changing the therapeutic concept. Potential targets include:

• Smaller insert dimensions
• Faster hydration and disintegration
• Lower friability
• Improved applicator loading
• Reduced insert breakage
• More stable low-dose content uniformity
• Lower packaging moisture transmission
• Improved handling during twice-weekly maintenance use
• Excipient systems that avoid lactose for specific patient segments
• Manufacturing processes with lower compression force and reduced tooling wear

A modified excipient system can support a new product only if it produces a meaningful clinical, usability, stability, or manufacturing advantage. Minor composition changes alone generally have limited commercial defensibility.

What formulation patents could protect a Yuvafem follow-on product?

The commercial value of an excipient patent depends on claim scope. A broad claim to estradiol in a vaginal insert may face prior-art pressure because vaginal estradiol tablets and inserts have been commercially developed for decades. More defensible claims are likely to focus on measurable formulation attributes or manufacturing controls.

Potential claim categories include:

Composition claims

A composition patent could cover:

• Specific ratios of estradiol, lactose, hypromellose, polyethylene glycol, and lubricant
• A defined polymer grade or molecular-weight range
• A narrow tablet-mass range
• Specific excipient limits that produce a target dissolution profile
• A lactose-free or low-lactose formulation
• A formulation with improved stability under defined humidity conditions

Composition claims are strongest when linked to unexpected technical performance, such as improved content uniformity, reduced degradation, or a clinically relevant dissolution profile.

Performance-defined claims

Claims may target measurable characteristics such as:

• Dissolution at specified time points
• Disintegration time
• Estradiol content uniformity
• Tablet tensile strength
• Friability
• Moisture content
• Impurity limits after accelerated storage

Performance claims can be commercially useful but require reproducible analytical methods and careful claim drafting. A dissolution profile alone may be difficult to enforce if competing products achieve the same profile through different compositions.

Manufacturing claims

Manufacturing intellectual property may cover:

• Ordered addition of estradiol and carrier excipients
• Geometric dilution or high-shear blending
• Lubrication time and lubricant concentration
• Compression force and dwell time
• In-process sampling for low-dose uniformity
• Film coating or surface-treatment conditions
• Moisture-controlled processing and packaging

Manufacturing patents can create barriers even when the final composition is not identical. Their value depends on whether competitors can design around the process without sacrificing yield or quality.

Applicator and packaging claims

Commercial differentiation may also come from the delivery system:

• Single-use applicators
• Applicators made from lower-cost or recyclable polymers
• Improved insert retention within the applicator
• Tamper-evident unit-dose packaging
• High-barrier blister systems
• Packaging that reduces moisture-driven degradation
• Dose-count or adherence packaging for twice-weekly use

These claims may provide more practical differentiation than narrow excipient patents.

What is the Orange Book and patent status for Yuvafem?

Yuvafem is associated with an FDA-approved estradiol vaginal insert product. Orange Book analysis should distinguish the reference product from approved generic estradiol vaginal inserts and should verify current patent and exclusivity listings directly in the FDA database.[2]

The key legal points are:

• Yuvafem is an NDA product, while generic estradiol vaginal inserts generally follow the ANDA pathway.
• Pharmaceutical-equivalence requirements limit the commercial freedom to change strength, dosage form, route, or active ingredient.
• A formulation change that creates a new dosage form, new indication, or clinically meaningful delivery difference may require a different regulatory pathway.
• A generic applicant may file a Paragraph IV certification against listed patents if it seeks approval before patent expiration.
• Paragraph IV litigation risk depends on the patents listed for the reference product and the timing of certification, notice, and suit.
• A formulation patent must be evaluated separately from patents covering method of use, manufacturing, packaging, or applicator technology.

Publicly available product labeling identifies the formulation and inactive ingredients, but the commercial decision requires a current Orange Book review of listed patents, pediatric exclusivity, patent-term extensions, and any regulatory exclusivity. Patent status can change through listing, delisting, expiration, terminal disclaimers, or litigation outcomes.[2,3]

When does Yuvafem lose exclusivity and face generic competition?

Yuvafem already operates in a genericized therapeutic category. The relevant commercial question is not whether generic competition can begin, but how effectively a new entrant can compete on price, supply reliability, pharmacy substitution, and patient usability.

Generic entry scenarios include:

Scenario	Product strategy	Main advantage	Main barrier
Standard ANDA	Reference-aligned estradiol insert	Lowest regulatory and development risk	Price competition
Authorized generic	Same or near-identical product under another label	Faster market access and manufacturing leverage	Limited differentiation
Private-label supply	Contract-manufactured vaginal insert	Retail and payer channel access	Dependence on capacity and quality systems
Reformulated insert	New excipient or tablet platform	Potential lifecycle or usability advantage	Additional regulatory and clinical risk
Device-led product	Insert plus improved applicator or packaging	Better patient experience	Device development and combination-product controls
Alternative dosage form	Ring, cream, gel, or softgel	Different dosing and patient preference	Separate formulation and clinical development

For an ANDA applicant, the most commercially attractive route is usually a reference-aligned product with a reliable supply chain and a lower cost of goods. Excipient innovation should support manufacturing economics rather than create unnecessary regulatory divergence.

Which excipient opportunities have the strongest commercial potential?

Lactose-free or lactose-reduced inserts

A lactose-free version could target patients or prescribers who prefer to avoid lactose-containing formulations. The commercial opportunity is limited unless the product offers a clear labeling, tolerance, or supply advantage. The development burden includes proving equivalent performance at a 10-mcg dose.

Faster-disintegrating inserts

A faster-disintegrating formulation may improve perceived convenience and reduce residue. The risk is an altered local exposure profile or a dissolution result outside the reference range. A technically successful product would need evidence that faster disintegration does not produce unacceptable variability.

Moisture-stable formulations

Moisture management is commercially important for low-dose tablets. A better excipient system combined with high-barrier blister packaging could reduce potency loss, impurity formation, and tablet softening. This opportunity is especially relevant for hot and humid markets.

Lower-cost direct-compression platforms

A formulation that uses robust direct compression, fewer processing steps, and wider manufacturing tolerances could improve gross margin. The opportunity is strongest for manufacturers with existing oral-solid-dose infrastructure and validated low-dose blending capabilities.

Applicator and adherence packaging

The product is administered intermittently after the loading phase. Calendarized packaging, dose reminders, and improved applicator ergonomics could support adherence and brand positioning. These improvements may be easier to protect through device, packaging, or design rights than through excipient claims.

How does Yuvafem compare with competing vaginal estrogen products?

Product category	Main formulation	Patient-use profile	Excipient opportunity
Yuvafem/Vagifem	10-mcg estradiol vaginal insert	Low-dose, intermittent maintenance	Tablet uniformity, disintegration, packaging
Estradiol cream	Semi-solid cream	Flexible dosing, more mess and handling	Preservative-free systems, metered delivery
Estradiol vaginal ring	Polymer ring	Long-duration dosing	Polymer release control and insertion comfort
Prasterone insert	Vaginal insert containing DHEA	Local hormonal therapy with different active ingredient	Polymer, mucoadhesive, and moisture-control systems
Ospemifene	Oral tablet	Systemic administration	Oral formulation and tolerability, not vaginal excipient competition

Yuvafem’s principal competitive strength is the low-dose tablet format. Its principal weaknesses are limited room for composition-based differentiation and the possibility that some patients prefer creams, rings, or non-estrogen alternatives.

What generic entry risks exist for Yuvafem?

The main risks are commercial rather than purely patent-driven:

1. Multiple generic suppliers can compress net pricing quickly.
2. Pharmacy substitution can reduce brand retention.
3. Manufacturing interruptions can shift contracts and formulary position.
4. A competitor with a lower-cost applicator or packaging configuration can undercut the reference product.
5. A reformulated product may fail to demonstrate comparable dissolution or local tolerability.
6. A narrow excipient patent may be designed around by changing excipient grade, ratio, or processing conditions.
7. Low-dose manufacturing failures can produce batch rejection and supply shortages.

For a follow-on manufacturer, the most important technical controls are low-dose blend uniformity, segregation prevention, lubricant optimization, moisture protection, and packaging integrity.

What licensing and partnering opportunities exist?

Potential licensing targets include:

• A finished-dose manufacturer with validated vaginal-tablet capacity
• An excipient supplier with a low-dose blending or co-processing platform
• A packaging company with high-barrier unit-dose systems
• A medical-device company with improved vaginal applicators
• A regional pharmaceutical company seeking a private-label menopause product
• A contract development and manufacturing organization with ANDA experience

The strongest deal structure would normally combine formulation know-how, regulatory documentation, manufacturing capacity, and channel access. A standalone excipient license is less attractive unless it delivers a measurable advantage in stability, dissolution, production yield, or local tolerability.

Key Takeaways

• Yuvafem is a 10-mcg estradiol vaginal insert with a low active load and a compact excipient system.
• The principal public-label excipients are lactose monohydrate, hypromellose, magnesium stearate, and polyethylene glycol.
• Reference-aligned development offers the lowest regulatory risk for generic entrants.
• The best commercial opportunities are moisture-stable formulations, low-cost manufacturing, improved packaging, and better applicators.
• Excipient patents are more defensible when tied to measurable performance or manufacturing advantages.
• Biosimilar risk does not apply because estradiol is a small-molecule active.
• Generic competition is already the central market risk; differentiation must come from cost, supply reliability, usability, or a new delivery system.
• Current Orange Book listings, patent expiry dates, and Paragraph IV exposure require verification against the live FDA database before a filing or licensing decision.

FAQs

Can a lactose-free Yuvafem alternative be developed?

Yes. A lactose-free estradiol vaginal insert could be developed, but the replacement excipient system would need to preserve content uniformity, tablet strength, disintegration, dissolution, stability, and local tolerability.

Is Yuvafem eligible for a 505(b)(2) reformulation?

A materially different product may qualify for a 505(b)(2) application, but a conventional equivalent vaginal insert is generally more consistent with the ANDA pathway. The regulatory route depends on the extent of formulation, dosage-form, labeling, and clinical differences.

Can a new excipient create market exclusivity for estradiol vaginal inserts?

A new excipient alone is unlikely to create strong exclusivity. Protection is more credible when the excipient produces a defined, non-obvious technical result and supports enforceable composition, performance, or manufacturing claims.

Are vaginal estradiol inserts subject to biosimilar competition?

No. Estradiol is a chemically synthesized small molecule. Competing products are generics, alternative dosage forms, or other branded hormonal therapies.

What is the most valuable improvement to Yuvafem’s commercial profile?

For a generic manufacturer, the highest-value improvement is usually lower cost of goods combined with dependable supply. For a branded lifecycle product, an improved applicator, moisture-stable packaging, or a meaningfully easier-to-use insert is more commercially promising than a minor excipient substitution.

References

1. U.S. Food and Drug Administration. (2024). Yuvafem (estradiol vaginal inserts) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. National Library of Medicine. (2024). DailyMed: Yuvafem, estradiol vaginal insert.